Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367814 | 1.00 | GRM4 (1.00) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL14698148 | 1.00 | GRM4 (1.00) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL15060591 | 1.00 | GRM4 (1.00) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL20277498 | 0.91 | GRM4 (0.83) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL17835239 | 0.84 | GRM4 (0.73) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL5950689 | 0.81 | GRM4 (0.68) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL18037299 | 0.81 | ALDH1A1 (0.78) | GRM4HTTRAB9APOLBKMT2A | |
| SCHEMBL7857347 | 0.81 | ALDH1A1 (0.78) | GRM4HTTRAB9APOLBKMT2A | |
| SCHEMBL10521314 | 0.81 | GRM4 (0.68) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL10521836 | 0.81 | GRM4 (0.68) | GRM4HTTRAB9APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366539-A1 | METHODS FOR TREATING AUTISM SPECTRUM DISORDERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2024-11-07 | — | — | US | claimed |
| EP-4395754-A1 | METHODS FOR TREATING AUTISM SPECTRUM DISORDERS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2024-07-10 | — | — | EP | claimed |
| WO-2023031379-A1 | METHODS FOR TREATING AUTISM SPECTRUM DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-03-09 | — | — | WO | claimed |
| CN-112566906-B | Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4 | 多曼治疗学公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240366539-A1 | METHODS FOR TREATING AUTISM SPECTRUM DISORDERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2024-11-07 | — | — | US | disclosed |
| EP-4395754-A1 | METHODS FOR TREATING AUTISM SPECTRUM DISORDERS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023031379-A1 | METHODS FOR TREATING AUTISM SPECTRUM DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-03-09 | — | — | WO | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11472806-B2 | Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2022-10-18 | — | — | US | disclosed |
| US-20220118117-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 4 | MASSACHUSETTS GEN HOSPITAL (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220089609-A1 | SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | DOMAIN THERAPEUTICS (FR) | 2022-03-24 | — | — | US | disclosed |
| EP-2595996-A2 | TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck Sharp & Dohme Corp. (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013060029-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013063100-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20120316188-A1 | PREPARATION OF 4-AMINO-THIAZOLES AND 3-AMINO-1,2,4-THIADIAZOLES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | BOLEA CHRISTELLE (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NISSAN MOTOR CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| WO-2012006760-A1 | TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012008999-A2 | TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20110319425-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110257179-A1 | NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257179-A1 | NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM2, GRM1 | GRM4 1/4885HTT 1053/4885RAB9A 2177/4885 |
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM1, GRM4, GRM3 | GRM4 2/4885HTT 2461/4885RAB9A 2294/4885 |
| US-20220118117-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 4 | GRM2, GRM4, GRM1 | GRM4 2/4885HTT 139/4885RAB9A 2826/4885 |
| US-20110319425-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM4, GRM2 | GRM4 2/4885HTT 1396/4885RAB9A 1982/4885 |
| US-20240366539-A1 | METHODS FOR TREATING AUTISM SPECTRUM DISORDERS | OXTR, GABRB3, GRM4 | GRM4 3/4885HTT 2047/4885RAB9A 2152/4885 |
| US-11472806-B2 | Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors | GRM3, GRM1, GRM2 | GRM4 6/4885HTT 810/4885RAB9A 1427/4885 |
| US-20120316188-A1 | PREPARATION OF 4-AMINO-THIAZOLES AND 3-AMINO-1,2,4-THIADIAZOLES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM2 | GRM4 1/4885HTT 1798/4885RAB9A 2871/4885 |
| US-20220089609-A1 | SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | GRIK4, GRM4, GRIA4 | GRM4 2/4885HTT 2028/4885RAB9A 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.